Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...
Publications
4 shownLong-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).
9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...
Frequent Co-Authors
Researcher Info
- h-index
- 4
- Publications
- 4
- Citations
- 6,341
- Institution
- University of California, San Francisco
External Links
Identifiers
- ORCID
- 0000-0002-6482-1954
Impact Metrics
h-index
4
h-index: Number of publications with at least h citations each.